Liminatus Pharma Inc. - LIMN Net Assets per Single Share

Graphic logo of Liminatus Pharma LLC (LIMN)

Despite strict FDA oversight and high R&D costs, Liminatus Pharma utilizes a virtual model by outsourcing laboratory tests to external contractors. This book value per share chart helps assess the company's liquidation cushion, where 0.27 indicates the value of this parameter. The innovative approach is based on creating "smart" vaccines that activate immunity to combat tumor recurrences.

LIMN: Liminatus Pharma Corp Net Asset Value per Share 05/02/2025 - 10/28/2026

liminatuspharma.com - analytical breakdowns and key metrics (LIMN)

- price and consensus price forecast:
Price Chart Liminatus Pharma Corp|LIMN - Consensus Target
- market capitalization data:
Market Value Liminatus Pharma LLC|LIMN - Business Value
- book capitalization data:
Net Assets per Single Share Liminatus Pharma|LIMN - Total Stockholders' Equity|Market Value to Book Value Ratio liminatuspharma.com|LIMN - Total Business Assets
- debt and liquidity data:
Total Debt to Capital Liminatus Pharma|LIMN - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Liminatus Pharma LLC|LIMN - Company Cumulative Debt|Debt to Book Capitalization Ratio Liminatus Pharma LLC|LIMN - Company Long-Term Debt|Company Short-Term Debt Liminatus Pharma
Fundamental company valuation:LIMN - Liminatus Pharma Corp
Flagship merchandise of Liminatus Pharma LLC

Book value per share determines the portion of equity attributable to a single security after deducting all liabilities, serving as a baseline measure of the business's tangible value. Analyzing the trend of the net book value per share allows for monitoring the rate at which Liminatus Pharma (LIMN) consumes resources for R&D projects until stable commercial revenue is generated from clinical trials.

Competitor analysis for Liminatus Pharma

IBRX: Net Assets per Single Share|IMCR: Accounting Value per Share|Net Assets per Single Share Janux Therapeutics|RCUS (arcusbio.com) - Equity per Share|Net Assets per Single Share ZYME (Zymeworks)|Net Asset Value per Share TNGX|Net Assets per Single Share Iovance IOVA|Equity per Share Immatics Biotechnologies (IMTX)|Xencor, Inc. - Book Value per Share|compasstherapeutics.com - Accounting Value per Share|REPL (Replimune) - Net Assets per Single Share|LYEL: Net Asset Value per Share|Innate Pharma, S.A. (IPHA) - Net Assets per Single Share|PYXS (Pyxis Oncology) - Net Assets per Single Share|Net Assets per Single Share CGEN (Compugen Ltd)|Net Asset Value per Share iobiotech.com|STRO: Book Value per Share|Book Value of One Share MiNK Therapeutics Inc. INKT|HOWL: Accounting Value per Share|IMMX - Net Asset Value per Share|Accounting Value per Share ALX Oncology Holdings (ALXO)|CUE - Accounting Value of a Share|pdsbiotech.com - Book Value per Share|SONN (Sonnet BioTherapeutics Holdings) - Net Assets per Share|Net Assets per Single Share MAIA|Accounting Value per Share LVTX|Net Assets per Single Share NXTC (NextCure, Inc.)|Accounting Value per Share leaptx.com LPTX|Accounting Value per Share INTS (Intensity Therapeutics, Inc.)|Sensei Biotherapeutics Inc - Book Value per Share|Synthetic Biologics (TOVX) - Net Assets per Single Share|GRTS: Equity per Share|Net Assets per Single Share KA|Net Asset Value per Share neximmune.com|Turnstone Biologics Corp - Accounting Value per Share|Book Value of One Share Vaccinex Inc. (VCNX)|Accounting Value per Share Harpoon Tx